Fund Holdings — Avoro Capital Advisors LLC

Total Portfolio Value:
$5.71B
Total Bought:
$518.30M
Total Sold:
$1.33B
Net Transaction:
-$815.06M
Notable People:
Behzad Aghazadeh, Avoro Capital L.P.
Securities
▲▼
SharesValue
Q1 2025
▲▼
Q2 2025
▲▼
Change
▲▼
Q1 2025
▲▼
Q2 2025
▲▼
Weight (%)
▲▼
Change
▲▼
Ascendis Pharma A/SADR(ASND)5,218,0004,980,000-238,000$813.28M$859.55M15.05%+$46.27M
United Therapeutics Corporation(UTHR)2,675,0002,370,000-305,000$824.62M$681.02M11.93%-$143.60M
argenx SEADR(ARGX)1,235,1771,175,000-60,177$731.06M$647.68M11.34%-$83.37M
Madrigal Pharmaceuticals, Inc.(MDGL)2,022,2221,875,000-147,222$669.82M$567.45M9.94%-$102.37M
Krystal Biotech, Inc.(KRYS)2,731,0002,660,000-71,000$492.40M$365.64M6.40%-$126.76M
Kymera Therapeutics, Inc.(KYMR)6,460,0006,555,555+95,555$176.81M$286.08M5.01%+$109.27M
Apellis Pharmaceuticals Inc.
COM
12,222,22212,222,2220$267.30M$211.57M3.71%-$55.73M
Avidity Biosciences Inc7,625,0007,050,000-575,000$225.09M$200.22M3.51%-$24.87M
MoonLake ImmunotherapeuticsCL A(MLTX)2,770,1004,150,000+1,379,900$108.23M$195.88M3.43%+$87.65M
Akero Therapeutics Inc03,500,000+3,500,000$0$186.76M3.27%+$186.76M
Soleno Therapeutics Inc2,525,0002,050,000-475,000$180.41M$171.75M3.01%-$8.66M
Xenon Pharmaceuticals Inc.(XENE)5,741,6665,400,000-341,666$192.63M$169.02M2.96%-$23.61M
Arrowhead Pharmaceuticals, Inc.(ARWR)11,111,11110,600,000-511,111$141.56M$167.48M2.93%+$25.92M
Merus N V3,000,0003,155,555+155,555$126.27M$165.98M2.91%+$39.71M
Vera Therapeutics, Inc.(VERA)5,701,9006,300,000+598,100$136.96M$148.43M2.60%+$11.47M
Amicus Therapeutics Inc.
COM
20,500,00018,000,000-2,500,000$167.28M$103.14M1.81%-$64.14M
Alkermes plc(ALKS)2,450,0002,900,000+450,000$80.90M$82.97M1.45%+$2.07M
Ocular Therapeutix, Inc.(OCUL)8,060,0007,400,000-660,000$59.08M$68.67M1.20%+$9.59M
89bio Inc6,350,0006,750,000+400,000$46.16M$66.28M1.16%+$20.12M
Centessa Pharmaceuticals PlcADR4,050,0005,000,000+950,000$58.24M$65.70M1.15%+$7.46M
uniQure N.V.(QURE)2,175,0003,625,000+1,450,000$23.05M$50.53M0.88%+$27.48M
Taysha Gene Therapies, Inc.(TSHA)19,999,99921,700,000+1,700,001$27.80M$50.13M0.88%+$22.33M
Blueprint Medicines Corp3,850,000375,000-3,475,000$340.76M$48.07M0.84%-$292.70M
Tourmaline Bio Inc2,425,0002,555,555+130,555$36.88M$40.86M0.72%+$3.98M
BioCryst Pharmaceuticals, Inc.(BCRX)8,700,0004,500,000-4,200,000$65.25M$40.32M0.71%-$24.93M
MannKind Corporation(MNKD)8,750,0005,850,000-2,900,000$44.01M$21.88M0.38%-$22.13M
Monte Rosa Therapeutics, Inc.(GLUE)4,645,5483,725,000-920,548$21.56M$16.80M0.29%-$4.76M
Septerna, Inc.(SEPN)1,337,5001,237,500-100,000$7.74M$13.08M0.23%+$5.34M
Ultragenyx Pharmaceutical Inc.(RARE)830,000330,000-500,000$30.05M$12.00M0.21%-$18.06M
Whitehawk Therapeutics, Inc.(WHWK)2,849,4022,849,4020$5.07M$5.33M0.09%+$256.4K
Autolus Therapeutics plcADR(AUTL)9,910,6420-9,910,642$15.36M$0—-$15.36M
Intra-Cellular Therapies Inc625,0000-625,000$82.45M$0—-$82.45M
Sarepta Therapeutics, Inc.(SRPT)2,674,8350-2,674,835$170.71M$0—-$170.71M
Vaxcyte, Inc.(PCVX)1,000,0000-1,000,000$37.76M$0—-$37.76M
Page 1 of 1
Avoro Capital Advisors LLC — 13F Holdings — Q2 2025 | TickerTrail